74 - Global Regulatory Harmonization (S5E14)

Have you ever felt like you're drowning in information?
Yeah. You're trying to understand something really
important, something that affects millions of
people, but there's just so much information
out there that it feels impossible to wrap your
head around it. Totally. It's like drinking from
a fire hose sometimes. Exactly. It's like trying
to drink from a fire hose. And I think a perfect
example of that is trying to figure out how a
new medicine actually gets from the lab all the
way to pharmacies around the world. Like all
the steps involved, all the regulations, all
the different countries. It can feel incredibly
overwhelming. It is a very complex process, that's
for sure. And that's exactly what we're going
to be tackling today. We're going to be offering
you a guided tour. OK. Through this crucial process.
I like it, a guided tour. Yeah, we're going deep.
We're doing a deep dive today. A deep dive. Love
it. OK. So are we talking about global regulatory
harmonization for drug approvals? You got it.
That's exactly what we're diving into. Okay,
great. Because for this deep dive, I have been
looking at a ton of materials. Everything from
the guidelines issued by regulatory bodies, like
the FDA. You know, that's the U .S. Food and
Drug Administration, the agency that makes sure
all our medicines in the United States are safe
and effective. And then, of course, we have the
International Council for Harmonization, or ICA,
to analyses of the drug development journey itself,
and even some really interesting case studies.
So we've got, like, the rule books, and then
we've got how it actually works in practice.
Yeah, we're looking at both sides of the coin.
I love it. Our goal with all of this is to extract
the core knowledge that you need to understand
this vital area. Exactly. Because whether you're
like me and you're just fascinated by how this
whole thing works, or maybe you're prepping for
a big meeting and you need to get up to speak
quickly. Yeah, if that makes sense. Or maybe
you just want to be in the know. You want to
be able to hold your own in a conversation. This
deep dive is for you. Perfect. Sounds like we've
got a good plan. Yeah. And our mission today...
is very straightforward to unpack all of the
global efforts that are aimed at making drug
approval standards more aligned across the world.
I see. And crucially we want to understand what
this all means for patients who are waiting for
those new therapies. Yeah, that's the key question,
isn't it? How does all this impact patients at
the end of the day? Exactly. All right, so where
do we even begin with something this big? It's
a huge topic. It is huge. And I think a good
place to start would be with the challenge. OK.
The challenge of diversity and regulatory standards.
Right, because around the globe, things are not
the same everywhere. They are not. And historically,
they have been very, very different. So if you
think about the major players, you've got the
US with the FDA, you've got Europe with the European
Medicines Agency, the EMA, which is kind of like
their equivalent of the FDA, but for the entire
European Union. Right, a central authority for
drug approval. Exactly, yeah. And then you've
got Japan with their Pharmaceuticals and Medical
Devices Agency, the PMDA. PMDA, yep. Got it.
So we've got these major markets. Huge market.
But for a long time, each of them was operating
with its own very distinct rules and expectations
for what a company had to prove to get a drug
approved. It sounds like a logistical nightmare.
It was. And it was really tough for drug developers
because if you're a company and you've. poured
your heart and soul into this potentially life
-saving drug, and you want to bring it to people
worldwide. Yeah. You're suddenly faced with all
these different hoops to jump through in each
region. So are we talking like they had to essentially
reinvent the wheel multiple times? Essentially,
yes. You had this patchwork of regulations, and
it meant that companies would have to spend so
much time, money, resources, developing separate
applications, sometimes even slightly different
preclinical studies. Like the early ones with
the animals. and in the lab. Exactly, those early
stage tests. And even the clinical trials, the
studies with human volunteers might need variations
just to satisfy the FDA versus the EMA versus
the PMDA. Well, that sounds incredibly inefficient.
It was. There's no doubt about it. And I mean,
I imagine that inefficiency could actually have
real world consequences. Oh, absolutely. Like
potentially delaying the availability of new
medicines for people who need them. That's exactly
right. It could slow down the whole process significantly.
So something had to change. Yeah. It was clear
that things couldn't. continue that way. So what
sparked the move towards harmonization? Like,
how did people start trying to fix this mess?
Well, this is where it gets really interesting.
So recognizing all these challenges, in the late
1980s and early 1990s, there was this pivotal
initiative that emerged. The International Council
for Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use.
Oh, wow. That's a mouthful. Yeah. It is, but
thankfully we just call it ICH. OK, the ICH.
So this was like a light bulb moment. Like, hey,
let's all get together and try to figure this
out. It was a major step forward. The ICH brought
together the regulatory authorities and the pharmaceutical
industry from these major regions to try and
find some common ground on the technical requirements
for drug registration. So the ICH is like this
big international forum where regulators from
different countries sit down and try to agree
on a common set of rules for drug approvals.
That's a great way to put it. Okay. And who are
like the key players? Who's sitting at that table?
The core participants have always been the agencies
from those big influential regions we talked
about, the FDA from the US, the EMA in Europe,
and the PMDA in Japan. Got it. And the ICH provides
a platform for them to come together in consultation
with the pharmaceutical industry, of course,
and try to reach a consensus on scientific and
technical guidelines. OK, so they're hashing
out the details of what good science looks like.
Exactly. So if they all agree on something, does
that automatically become law everywhere? That's
an important point. While ICH guidelines are
super influential and widely adopted, the ICH
itself doesn't have the legal authority to force
countries to follow them. I see. It's more like
a really strong recommendation, a gold standard,
if you will. Like, we all agree this is the best
way to do it. Exactly. It's a best practices
guide for the whole world. OK, so we've got this
push for harmonization. Right. But how does it
actually play out in the real world? Okay, great
question. So let's think about the entire process
of developing a new medicine from those first
ideas in the lab. all the way to submitting all
the paperwork for approval. It's like the entire
journey. The whole thing. Right. And harmonization
efforts actually impact almost every single stage.
Wow. For example, let's start with preclinical
and nonclinical programs. So this is like before
it even gets to humans. Exactly. The very early
stages. OK. The ICH aims to create more consistent
guidance on the types of studies needed. to evaluate
a drug's safety and potential effectiveness before
it ever reaches a human being. So this is all
about making sure it's even worth testing in
people. Exactly. And the idea is to reduce the
need for companies to conduct the same studies
multiple times in different regions. Oh, I see.
Just because each country has slightly different
rules. So streamline that early process. Yeah.
Make it more efficient. Save time and resources.
Makes a lot of sense. It does. And it allows
those resources to be used elsewhere, which is
really important. OK, so what about clinical
trials? I mean, that feels like a super cr -
critical stage. It is. It's where we really start
to see how the drug works in humans. And you
can imagine in the past, there might've been
different ethical or scientific standards, which
would make things very complicated. So how has
the ICH tackled that? They've actually made huge
progress in this area. Okay, good. They've developed
really comprehensive guidelines covering all
the ethical and scientific principles that should
govern how clinical trials are designed, conducted,
recorded, and reported. So like a global rule
book for running these trials. Exactly. And it's
often referred to as Good Clinical Practice,
or GCP for short. GCP, got it. And by sticking
to these ICH GCP guidelines, companies can be
much more confident that the data they generate
from their clinical trials in one region will
be accepted by regulatory agencies in other ICH
countries. So they're not going to get pushback
from the FDA if they ran their trials in Europe.
according to these guidelines. Ideally, no. It
builds trust and makes the whole process much
smoother. So it's about making sure everyone's
speaking the same language when it comes to clinical
trials. Exactly. It's about setting a global
standard for quality and reliability. That makes
sense. It makes the global evaluation of a drug
much more streamlined, which is good news for
everyone. It sounds like a win -win. It is, and
it helps get those treatments to people who need
them faster. Absolutely. Okay, so we've covered
the early research in clinical trials. What about
the final step? You mean the actual application
process for drug approval? Yeah, like all the
paperwork, the data, the big submission. Right,
what's often called the regulatory submission.
It's a big deal. It involves compiling everything
they've learned about the drug. Everything. Everything.
All the data, all the findings. And the ICH has
also been working to harmonize the technical
requirements for what information needs to be
included in these submissions. OK. So they're
trying to make it so companies don't have to
create completely different applications for
every country. That's exactly it. It's about
reducing that burden and making the process more
efficient. So instead of having to create like
a separate dossier for the FDA and a separate
one for the EMA and another one for the PMDA.
Yeah, it's a lot of paperwork. It's more like
one standardized package that everyone can work
with. You got it. It's a huge step towards streamlining
the global approval process. So it sounds like
this global regulatory harmonization has the
potential to be really beneficial. It does. It's
about working smarter, not harder. But in practical
terms, what are the biggest advantages? Well,
first and foremost, as we've been talking about,
it cuts down on redundancy. Like all those repeated
studies we talked about. Exactly. Companies can
potentially avoid having to repeat those expensive
and time -consuming studies just because different
regions have slightly different rules. Saves
time, saves money. Huge cost savings, which is
a big deal for these companies. Right, because
that frees up resources to invest in more research
and development. Precisely. It allows them to
focus on innovation and bringing new treatments
to market. And then ultimately that benefits
patients. Absolutely. That's the whole point.
Because if things are more efficient and streamlined,
those promising new drugs can get to the people
who need them faster. Exactly. And that's especially
important for diseases where there aren't a lot
of good treatment options currently available.
Right. Like if we're facing a global health crisis,
we need to be able to get those treatments out
there. as quickly and safely as possible. And
harmonization can definitely help with that.
So it's about speed, but it's also about efficiency
across the entire process. It is. It's about
making the whole drug development lifecycle more
efficient, from the initial discovery all the
way to a patient being able to access the treatment.
Okay, so I'm starting to see how this all fits
together. Good, I'm glad to hear it. But even
with all these efforts, I have to imagine there
are still some differences. Oh, for sure. in
how drugs are approved around the world. Yeah,
it's not a perfectly uniform system. It can't
be that simple, right? It would be lovely if
it were, but the reality is a bit more complicated.
So what are some of the things that are still
different? Like, where do those variations still
exist? Okay, so a big one is that while the ICH
provides a really valuable framework and a lot
of guidance... Right. local country regulations
still play a big role. Right. Every country has
its own specific laws. Exactly. So even if a
company has followed all the ICH guidelines to
the letter, they still have to meet the specific
requirements of each country where they want
to sell their product. So it's like ICH sets
the international baseline. Right. But then each
country adds its own layer of specific rules
on top of that. Yeah, that's a good way to think
about it. Like, let's say a company wants to
market their drug in China. even if they've met
all the ICH standards, they might still need
to adjust their manufacturing processes or meet
specific conditions for marketing authorization
that are unique to China. So there's still that
local adaptation that needs to happen. Exactly.
The ICH helps harmonize things, but it doesn't
completely erase those national differences.
Makes sense. And what about the legal power of
these guidelines? Like we talked about how the
ICH doesn't have the authority to enforce its
recommendations. Right. That's a key point. In
the United States, for example, the FDA's regulations,
like those found in Title 21 of the Code of Federal
Regulations, those are legally binding. They
are the law of the land. So companies have to
follow those FDA regulations. No questions asked.
Yep. Those are non -negotiable. But ICH guidelines,
on the other hand, they represent a consensus
view, a set of best practices that were developed
collaboratively. Agencies like the FDA can choose
to adopt and implement those guidelines, which
effectively makes them part of their requirements,
but the ICH itself can't punish a country for
not following them. So it's like a strong suggestion,
but not a legal mandate. That's a great way to
put it. It's all about collaboration and consensus
building. So the ICH... facilitates the agreement,
but ultimately it's up to each individual agency,
like the FDA or the PMDA, to actually give that
final stamp of approval. They hold the power
within their own territories. So in this more
harmonized world, what's the role of those agencies
then? Like, how are they adapting their review
processes? Their core responsibility hasn't changed.
They still have to independently review and approve
new drugs and medical devices within their own
countries or regions. Right. They're still the
gatekeepers. Absolutely. They're the ones who
carefully evaluate all the scientific data submitted
by companies and determine if a product is truly
safe and effective for its intended use. And
that's a huge responsibility. It is. They're
protecting the public health. So even though
there's this push for harmonization, they're
not just going to rubber stamp everything. No,
they still need to do their due diligence and
make sure every product meets their standards.
But what harmonization does is help to make those
reviews more consistent by establishing clearer
and more aligned expectations for the type and
quality of data that companies need to provide.
So everybody's on the same page about what good
science looks like. Exactly. Which can lead to
more predictable review timelines, which is helpful
for everyone involved. So at the end of the day,
no matter how harmonized this whole process gets,
the number one priority for all these regulatory
bodies is still making sure those medicines are
safe, effective, and high quality. 100%. Protecting
public health is their top priority. And harmonization
is just a tool to help them do that more effectively
on a global scale. Exactly. It's about working
together to ensure that new treatments are both
safe and accessible to everyone who needs them.
It's really fascinating to think about how these
global collaborations and this whole push for
harmonization are often driven by these huge
global health challenges. Absolutely. When you
have a pandemic, the ability to quickly develop
and deploy effective treatments across borders
becomes absolutely critical. And that's when
those differences in regulations can really become
a major obstacle. It's true. They can slow things
down significantly. So in those situations, harmonization
isn't just about efficiency. It's about saving
lives. It absolutely can be. And that's why these
efforts are so important. It's about making sure
those life -saving treatments can reach everyone
who needs them, no matter where they live. OK.
So let's recap what we've learned today. All
right. Let's do it. We started by looking at
how all the different regulatory standards around
the world were creating this really complex and
inefficient system for drug development. Right,
a lot of hoops to jump through. And then we talked
about how the ICH emerged as this global effort
to try and harmonize those standards. Yep, bringing
everyone to the table. And we dug into the roles.
of the big players, the FDA, the EMA, the PMDA.
The key regulatory agency. And how they're working
together to make this happen. Through collaboration
and consensus. We also looked at how harmonization
affects the different stages of bringing a new
drug to market. Right, from those early studies
all the way to the final approval. And we talked
about the potential benefits, like reducing all
that duplicated effort. Yeah, less redundancy.
And speeding up access for patients. Which is
ultimately what it's all about. Absolutely. But
we also acknowledge that even with all this progress,
there are still some differences between countries.
Yeah, some variations are always going to exist.
And that those local regulations still matter
a lot. They do. Each country has its own unique
considerations. And at the end of the day, agencies
like the FDA and EMA, their top priority remains
ensuring those medicines are safe and effective.
Right. They're the guardians of public health.
For everyone. Exactly. That's their core mission.
So I feel like I have a much better understanding
of this whole process now. I'm glad to hear that.
It's a complex topic, but it's important to understand.
Absolutely. So for our final thought today, I
want to leave you with a question to ponder.
OK, I like it. Hit me with your question. Given
all the complexities we've talked about the global
health needs the varying prevalence of diseases
in different regions Right and the local regulatory
priorities that might sometimes be different.
Yeah, those local nuances can be tricky What
do you think of the biggest remaining hurdle
in achieving truly global harmonization of drug
approvals? Wow, that's a big question and then
building on that What do you think a future with
even greater harmonization might look like? That's
an interesting thought experiment. I think it
would involve even closer collaboration between
regulatory agencies, increased transparency and
information sharing, and perhaps even more standardized
approaches to things like data collection and
analysis. So it's about building crust and finding
common ground. Exactly. It's a big challenge,
but the potential benefits are huge. It definitely
is something to think about. So thanks for joining
us for this deep dive today. It's been a fascinating
conversation. It has been. Thanks for having
me. I always enjoy exploring these complex issues
with you. And to all our listeners out there,
keep asking those tough questions and stay curious
about the world around you. Until next time.
See them. Bye.